论文部分内容阅读
应用 PCR 技术,以 SIL-TAL-1、HRX 基因相合的,和 bcr/ab1以及 PML-RAR_α4种融合基因作为肿瘤特异标志,对7例小儿急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)和16例小儿急性早幼粒细胞白血病(acute promyecytic leukemia,APL)在完全缓解(complete remission,CR)后的微量残留病(minimal residual disease,MRD)作系统的跟踪检测。结果所有的小儿 ALL 和 APL 在 CR 后均存在MRD,MRD 持续检测阴性,提示可能临床治愈,若 MRD 持续阳性或由阴转阳则提示将发生骨髓复发。检测的灵敏度是10~(-4)～10~(-6)。白血病 MRD 的跟踪检测有重要的临床意义。
The fusion gene of SIL-TAL-1, HRX, bcr / ab1 and PML-RAR_α were used as tumor-specific markers by PCR. Seven cases of acute lymphoblastic leukemia (ALL) and 16 cases of acute lymphoblastic leukemia Systemic follow-up testing of minimal residual disease (MRD) in children with acute promyecytic leukemia (APL) after complete remission (CR) was performed. Results All pediatric ALL and APL had MRD after CR, and the negative results of MRD persisted, suggesting that they may be clinically cured. If the MRD is persistent or the yin-yang is positive, bone marrow recurrence will occur. Sensitivity of detection is 10 ~ (-4) ~ 10 ~ (-6). The detection of leukemia MRD has important clinical significance.